29 completed, 6 terminated, 4 unknown, 2 withdrawn. 20 Phase 2, 15 Phase 1, 8 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Bexarotene: new trials by email Literature Review of Bexarotene trials Research Report on Bexarotene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel - Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma | Not applicable | Withdrawn | Case Comprehensive Cancer Center | 2022-04-01 | 2025-06-12 | |
| A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides Bexarotene, Total Skin Electron Beam (TSEB) - Cutaneous T-cell Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-03-16 | 2026-02-04 |
| The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC Bexarotene, Capecitabine - Metastatic Triple-Negative Breast Carcinoma | Phase 1 | Completed | National Cancer Centre, Singapore | 12 | 2020-10-01 | 2025-09-23 |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer Bexarotene, Questionnaire Administration - Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2018-06-15 | 2023-01-10 |
| A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects Bexarotene, Placebo - Alzheimer's Disease | Phase 1 | Completed | ReXceptor, Inc. | 12 | 2014-08-01 | 2015-08-13 |
| Bexarotene Amyloid Treatment for Alzheimer's Disease Bexarotene, Placebo - Alzheimer's Disease | Phase 2 | Completed | The Cleveland Clinic | 20 | 2013-02-01 | 2016-02-12 |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Brentuximab Vedotin, Methotrexate, Bexarotene - Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 131 | 2012-06-11 | 2021-01-05 |
| Phase I Study of CS-7017 and Bexarotene CS-7017 and Bexarotene - Solid Tumors, Lymphoma | Phase 1 | Terminated | Georgetown University | 9 | 2011-12-01 | 2017-02-14 |
| Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia Bexarotene - Acute Myeloid Leukemia | Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 24 | 2010-05-25 | 2020-12-17 |
| Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Decitabine, Bexarotene - Leukemia, Myeloid, Acute | Phase 1 | Completed | Washington University School of Medicine | 19 | 2010-05-01 | 2014-07-29 |
| Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Pralatrexate Injection, Bexarotene Capsules, Vitamin B12 - Cutaneous T-cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | Acrotech Biopharma Inc. | 34 | 2010-03-01 | 2019-12-18 |
| Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) Bexarotene - Refractory Cutaneous T-cell Lymphoma | Phase 4 | Completed | Bausch Health Americas, Inc. | 59 | 2010-01-06 | 2019-11-12 |
| Preoperative Bexarotene Treatment for Cushing's Disease Bexarotene - Cushing's Disease | Phase 1 / Phase 2 | Unknown | University of Virginia | 6 | 2008-11-01 | 2011-05-30 |
| Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia Bexarotene (Targretin LGD1069), bexarotene - Schizophrenia | Phase 3 | Completed | Beersheva Mental Health Center | 90 | 2008-11-01 | 2012-07-26 |
| A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression Bexarotene - Thyroid Cancer | Early Phase 1 | Completed | University of Colorado, Denver | 10 | 2008-11-01 | 2014-01-17 |
| Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma bexarotene, gemcitabine hydrochloride - Lymphoma | Phase 2 | Completed | University College, London | 36 | 2008-03-01 | 2014-12-03 |
| Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer bexarotene, capecitabine, carboplatin - Lung Cancer | Phase 2 | Unknown | Raghu Nandan, M.D., Inc | 39 | 2007-01-01 | 2014-01-10 |
| BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Bexarotene, Erlotinib - Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2006-11-29 | 2020-01-29 |
| Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia sargramostim, bexarotene, cytogenetic analysis - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 26 | 2006-11-01 | 2018-10-05 |
| Study of Tarceva and Targretin in Stage I-II Lung Cancer erlotinib (Tarceva) and bexarotene (Targretin) - Carcinoma, Non-small-cell Lung | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 12 | 2005-12-01 | 2019-01-08 |
Showing 20 of 42. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (12) · Mycosis Fungoides (11) · Carcinoma, Non-Small-Cell Lung (7) · Lymphoma (7) · Sezary Syndrome (7) · Leukemia, Myeloid, Acute (4) · Lung Neoplasms (3) · Schizophrenia (3) · Alzheimer Disease (2) · Breast Neoplasms (2) · Carcinoma (2) · Leukemia (2) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (2) · Acquired Immunodeficiency Syndrome (1) · Aggression (1)
Beersheva Mental Health Center (3) · Dartmouth-Hitchcock Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · Abramson Cancer Center at Penn Medicine (2) · Eisai Inc. (2) · Ligand Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · Acrotech Biopharma Inc. (1) · Bausch Health Americas, Inc. (1) · Baylor Breast Care Center (1) · Boston University (1) · Case Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fox Chase Cancer Center (1) · Georgetown University (1)
United States (34) · Israel (5) · France (4) · United Kingdom (4) · Austria (3) · Germany (3) · Italy (3) · Spain (3) · Australia (2) · Belgium (2) · Canada (2) · Hungary (2) · Poland (2) · Switzerland (2) · Brazil (1)
David J. Straus, MD (2) · Konstantin H Dragnev, MD (2) · Mack Mabry, M.D. (2) · Vladimir Lerner, MD, PhD (2) · Amanda Cashen, M.D. (1) · B. Douglas Smith, MD (1) · Brandon Imber, MD (1) · Chanoch Miodownik, MD (1) · Charlotte D Jacobs (1) · Craig T Curtis, MD (1) · Donald E Tsai, M.D., Ph.D. (1) · Donald E. Tsai, MD, PhD (1) · Elaine Lim, MD (1) · George D. Demetri, MD (1)
PMID 32632956, PMID 12637463, PMID 17366595, PMID 17515522, PMID 18303488, PMID 22239668, PMID 22586319, PMID 22924950, PMID 23442309, PMID 24285015, PMID 24434091, PMID 26822146, PMID 28600132, PMID 29067298, PMID 32502876, PMID 33794441, PMID 34507350
2004 (1), N01CN00034 (1), P30CA006973 (1), P30CA016672 (1), U19CA086809 (1)